Cargando…
Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma
INTRODUCTION: In the peri-elimination setting, the positive predictive value of trachomatous inflammation–follicular (TF), the primary marker used to determine need for antibiotics for trachoma, is suboptimal. Here, three non-TF measures are used to compare two regions where TF prevalence exceeds th...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113835/ https://www.ncbi.nlm.nih.gov/pubmed/32017971 http://dx.doi.org/10.1016/j.jinf.2020.01.015 |
_version_ | 1783513755887337472 |
---|---|
author | Butcher, Robert Handley, Becca Garae, Mackline Taoaba, Raebwebwe Pickering, Harry Bong, Annie Sokana, Oliver Burton, Matthew J Sepúlveda, Nuno Cama, Ana Mesurier, Richard Le Solomon, Anthony W. Mabey, David Taleo, Fasihah Tekeraoi, Rabebe Roberts, Chrissy h |
author_facet | Butcher, Robert Handley, Becca Garae, Mackline Taoaba, Raebwebwe Pickering, Harry Bong, Annie Sokana, Oliver Burton, Matthew J Sepúlveda, Nuno Cama, Ana Mesurier, Richard Le Solomon, Anthony W. Mabey, David Taleo, Fasihah Tekeraoi, Rabebe Roberts, Chrissy h |
author_sort | Butcher, Robert |
collection | PubMed |
description | INTRODUCTION: In the peri-elimination setting, the positive predictive value of trachomatous inflammation–follicular (TF), the primary marker used to determine need for antibiotics for trachoma, is suboptimal. Here, three non-TF measures are used to compare two regions where TF prevalence exceeds the threshold for intervention, but where the Chlamydia trachomatis (Ct) prevalence is different. METHODS: Population prevalence of trachoma was measured in Vanuatu (n = 3470) and Kiribati (n = 2922). Dried blood spots (DBS) and conjunctival photographs were collected from every survey participant, and conjunctival swabs were collected from those aged 1–9 years. Individuals were tested for blood anti-Pgp3 antibodies, Ct DNA at the conjunctiva and severity of conjunctival scarring. RESULTS: The prevalence of TF in 1–9-year-olds was 16.5% in Vanuatu and 38.2% in Tarawa. 7% of people aged ≥1 year in Vanuatu had conjunctival scarring compared to 27% in Tarawa. The prevalence of ocular Ct infection in 1–9-year-olds was 1.5% in Vanuatu and 27.4% in Tarawa. The seroconversion rate amongst 1–9-year-old children in Vanuatu and Tarawa was 0.018 and 0.197 events per child per year, respectively. CONCLUSIONS: Comparing Vanuatu to Tarawa demonstrates several markers that could be used to differentiate the trachoma status of populations in these (and other) locations. |
format | Online Article Text |
id | pubmed-7113835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | W.B. Saunders |
record_format | MEDLINE/PubMed |
spelling | pubmed-71138352020-04-06 Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma Butcher, Robert Handley, Becca Garae, Mackline Taoaba, Raebwebwe Pickering, Harry Bong, Annie Sokana, Oliver Burton, Matthew J Sepúlveda, Nuno Cama, Ana Mesurier, Richard Le Solomon, Anthony W. Mabey, David Taleo, Fasihah Tekeraoi, Rabebe Roberts, Chrissy h J Infect Article INTRODUCTION: In the peri-elimination setting, the positive predictive value of trachomatous inflammation–follicular (TF), the primary marker used to determine need for antibiotics for trachoma, is suboptimal. Here, three non-TF measures are used to compare two regions where TF prevalence exceeds the threshold for intervention, but where the Chlamydia trachomatis (Ct) prevalence is different. METHODS: Population prevalence of trachoma was measured in Vanuatu (n = 3470) and Kiribati (n = 2922). Dried blood spots (DBS) and conjunctival photographs were collected from every survey participant, and conjunctival swabs were collected from those aged 1–9 years. Individuals were tested for blood anti-Pgp3 antibodies, Ct DNA at the conjunctiva and severity of conjunctival scarring. RESULTS: The prevalence of TF in 1–9-year-olds was 16.5% in Vanuatu and 38.2% in Tarawa. 7% of people aged ≥1 year in Vanuatu had conjunctival scarring compared to 27% in Tarawa. The prevalence of ocular Ct infection in 1–9-year-olds was 1.5% in Vanuatu and 27.4% in Tarawa. The seroconversion rate amongst 1–9-year-old children in Vanuatu and Tarawa was 0.018 and 0.197 events per child per year, respectively. CONCLUSIONS: Comparing Vanuatu to Tarawa demonstrates several markers that could be used to differentiate the trachoma status of populations in these (and other) locations. W.B. Saunders 2020-04 /pmc/articles/PMC7113835/ /pubmed/32017971 http://dx.doi.org/10.1016/j.jinf.2020.01.015 Text en © 2020 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Butcher, Robert Handley, Becca Garae, Mackline Taoaba, Raebwebwe Pickering, Harry Bong, Annie Sokana, Oliver Burton, Matthew J Sepúlveda, Nuno Cama, Ana Mesurier, Richard Le Solomon, Anthony W. Mabey, David Taleo, Fasihah Tekeraoi, Rabebe Roberts, Chrissy h Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma |
title | Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma |
title_full | Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma |
title_fullStr | Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma |
title_full_unstemmed | Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma |
title_short | Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma |
title_sort | ocular chlamydia trachomatis infection, anti-pgp3 antibodies and conjunctival scarring in vanuatu and tarawa, kiribati before antibiotic treatment for trachoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113835/ https://www.ncbi.nlm.nih.gov/pubmed/32017971 http://dx.doi.org/10.1016/j.jinf.2020.01.015 |
work_keys_str_mv | AT butcherrobert ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT handleybecca ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT garaemackline ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT taoabaraebwebwe ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT pickeringharry ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT bongannie ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT sokanaoliver ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT burtonmatthewj ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT sepulvedanuno ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT camaana ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT mesurierrichardle ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT solomonanthonyw ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT mabeydavid ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT taleofasihah ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT tekeraoirabebe ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma AT robertschrissyh ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma |